Neurocysticercosis Clinical Trial
Official title:
Natural History of Treated Neurocysticercosis and Long-Term Outcomes
Neurocysticercosis is a brain disease due to the larval stage of the pork tapeworm (Taenia solium). The most common symptoms patient experience from infection inside the substance of the brain (parenchymal disease) are seizures and headaches. When the infection is either inside the fluid pockets inside the brain (ventricular disease) or in the space around the brain (subarachnoid disease) patients can have chronic headaches, relapsing aseptic meningitis, hydrocephalus, stroke, and may require neurosurgical intervention. The purpose of this study is to treat patients with anthelmintic therapy (praziquantel and/or albendazole) and anti-inflammatories in alignment with currently accepted best practices and guidelines, depending on the neurocysticercosis subtype. The purpose of the study is to better understand and characterize clinical, biologic, and management factors during treatment that influence long term outcomes. In order to understand this further we collect patient information, blood, urine samples, and additional cerebral spinal fluid if already being collected for clinical care....
The purpose of this protocol is to follow participants with cysticercosis during and after completion of treatment, to characterize the disease course during both short- and long-term follow-up, assess biomarkers associated with infection and response to treatment, improve diagnostic assays, and explore host-parasite interactions. Cysticercosis is defined as an infection with the larval form of Taenia solium and includes infection of the brain (neurocysticercosis [NCC]) that accounts for most of the symptomatic disease and serious complications. Evaluation and treatment will be provided as clinically indicated. Clinical data and biospecimens will be collected during and after treatment to assess biomarkers of infection and inflammation, immunologic response to treatment, and correlations between biomarkers and results of clinically indicated diagnostic tests. In addition, we will collect information from patient-reported outcome questionnaires completed by participants to better understand the long-term effect on functional ability and determine if there is a correlation between clinical deficits with biomarkers of inflammation. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00526916 -
PET Imaging of Peripheral Benzodiazepine Receptors in Patients With Neurocysticercosis Using [C-11]PBR28
|
Phase 1 | |
| Completed |
NCT00527579 -
PET Imaging of Peripheral Benzodiazepine Receptors in Patients With Neurocysticercosis Using [F-18]FB
|
Phase 1 | |
| Terminated |
NCT02233855 -
People Presenting With Neurocysticercosis in North America
|
||
| Completed |
NCT02234570 -
Phase I Trial Evaluating the Safety and Pharmacokinetics of Oxfendazole
|
Phase 1 | |
| Terminated |
NCT02947581 -
Sub Arachnoid Neurocysticercosis Treatment Outcome (SANTO)
|
Phase 3 | |
| Completed |
NCT02243644 -
Effects of 2 Different Duration of Albendazole Therapy in Patients With Neurocysticercosis in Brain ≤ 5 Lesions on CT
|
Phase 3 | |
| Not yet recruiting |
NCT06376396 -
Assessment of Combined Praziquantel and Albendazole vs Albendazole Alone to Treat Active Parenchymal Neurocysticercosis
|
Phase 4 | |
| Completed |
NCT03874689 -
Investigation of Environmental Factors Associated With Transmission of T. Solium in Endemic Villages of Zambia
|
||
| Completed |
NCT00441285 -
Neurocysticercosis: Combined Treatment With Praziquantel (PZQ) and Albendazole (ABZ)
|
Phase 2/Phase 3 | |
| Not yet recruiting |
NCT04706819 -
Parenchymal and Extraparenchymal Neurocysticercosis-A Registry Based Study
|
||
| Completed |
NCT00283699 -
A Pilot Study of Neurocysticercosis Treatment
|
Phase 3 | |
| Terminated |
NCT02945527 -
Treatment of Peri-calcification Edema in Neurocysticercosis (NCC)
|
Phase 2/Phase 3 | |
| Completed |
NCT00290823 -
Corticosteroids to Reduce Frequency of Seizures in Neurocysticercosis Patients
|
Phase 3 | |
| Completed |
NCT03834337 -
Treatment of Patients With Active Neurocysticercosis in Eastern Africa
|
||
| Completed |
NCT03851419 -
The Burden of (Neuro)Cysticercosis Among People Living With HIV in Rural Tanzania
|